Address of Corresponding Author

Pathophysiol Haemos Thromb 2005;34 (Suppl. 1):25-30 (DOI: 10.1159/000083081)

  Key Words

• Stroke prevention
• Oral direct thrombin inhibitors
• Oral vitamin K antagonists
• Ximelagatran
• Warfarin
• Non-valvular atrial fibrillation
• SPORTIF lll
• SPORTIF V

  Abstract

Atrial fibrillation (AF) is the most common cardiac risk factor for stroke. Oral anticoagulants such as the vitamin K antagonist warfarin have been proven effective in reducing the risk of stroke in AF. Warfarin, however, has many disadvantages including the need for coagulation monitoring, a narrow therapeutic index, inter-/intra-patient variability and food-drug interactions. As a result, warfarin is underused in clinical practice and a viable alternative is needed. Ximelagatran, the first oral direct thrombin inhibitor, is given as a fixed dose, does not have a narrow therapeutic index, has low potential for drug interactions, has no significant food interactions and does not require coagulation monitoring. Ximelagatran has been evaluated in the Stroke Prevention using an ORal direct Thrombin Inhibitor in atrial Fibrillation (SPORTIF) trial programme, the largest clinical trials of antithrombotic therapy for stroke prevention in AF to date. The phase III trials, SPORTIF III and V, compared ximelagatran (36 mg twice daily) with well-controlled warfarin (international normalized ratio 2.0-3.0) in a combined population of more than 7,000 moderate- to high-risk AF patients. Data from SPORTIF III show an absolute reduction in stroke and systemic embolic events with ximelagatran compared with warfarin at 21 months (1.6 vs. 2.3% per year, respectively; p = 0.10). Preliminary data from SPORTIF V appear to further support non-inferiority between the two agents. On-treatment analysis of the rate of major bleeding events shows an absolute, nonsignificant reduction in the event rate per year with ximelagatran versus warfarin in both studies. The results of SPORTIF III and V demonstrate that a fixed oral dose of ximelagatran, without coagulation monitoring, is comparable to dose-adjusted warfarin in preventing stroke and other thromboembolic complications among moderate- to high-risk AF patients and has a lower rate of both major and minor bleeding. With its positive benefit-risk ratio, ximelagatran may increase the population of eligible patients for anticoagulation with AF and maximize the potential of anticoagulation in the prevention of stroke.

Copyright © 2005 S. Karger AG, Basel

  References

1.

Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ: Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004;110:1042-1046.

2.

Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988.

3.

Hart RG, Halperin JL: Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention. Ann Intern Med 1999;131:688-695.

4.

Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998;158:1316-1320.

5.

Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB: Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229-234.

6.

Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.

7.

Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;22:1852-1923.

8.

Lip GYH, Hart RG, Conway DS: Antithrombotic therapy for atrial fibrillation. Br Med J 2002;325:1022-1025.

9.

Albers GW: Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 1994;154:1443-1448.

10.

Gottlieb LK, Salem-Schatz S: Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-1953.

11.

Lip GYH, Tean KN, Dunn FG: Treatment of atrial fibrillation in a district general hospital. Br Heart J 1994;71:92-95.

12.

Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA: Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998;352:1167-1171.

13.

Casey M, Hanley K: A measurement of the efficacy of anticoagulation monitoring in a general practice based setting. Ir Med J 2001;94:245-246.

14.

Brophy MT, Snyder KE, Gaehde S, Ives C, Gagnon D, Fiore LD: Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc 2004;52:1151-1156.

15.

Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.

16.

The Stroke Prevention in Atrial Fibrillation Investigators: Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-416.

17.

Wells PS, Holbrook AM, Crowther NR, Hirsh J: Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-683.

18.

Williams E, Ansari M, Lip GY: Managing atrial fibrillation in the Accident and Emergency department. QJM 2001;94:609-614.

19.

Lip GYH, Zarifis J, Watson RD, Beevers DG: Physician variation in the management of patients with atrial fibrillation. Heart 1996;75:200-205.

20.

Lip GYH, Kamath S, Jafri M, Mohammed A, Bareford D: Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: The West Birmingham Atrial Fibrillation Project. Stroke 2002;33:238-242.

21.

Halperin JL: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-438.

22.

The Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 2003;362:1691-1698.

23.

The Executive Steering Committee on behalf of the SPORTIF V Investigators: Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V). Circulation 2003;108(supplement):2723 (J).

24.

Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999;131:492-501.

25.

Halperin JL for the Executive Steering Committee on behalf of the SPORTIF V investigators. Stroke prevention using the oral thrombin inhibitor ximelagatran in patients with atrial fibrillation (SPORTIF V). American Heart Association. Orlando, Florida, 9-12 November 2003.

26.

Albers GW on behalf of the SPORTIF Investigators. Ximelagatran, an oral direct thrombin inhibitor, compared with dose-adjusted warfarin for primary and secondary stroke prevention in patients with AF. American Academy of Neurology. San Francisco, California. Oral presentation available at http://strokecenter.stanford.edu/docs/AAN04_SP_V_final.ppt [accessed October 2004], 24 April-1 May 2004.

  Author Contacts

Prof. Gregory Y.H. Lip
University Department of Medicine
City Hospital, Dudley Road
Birmingham, B18 7QH (UK)
Tel. +44 121 507 5080, Fax +44 121 554 4083, E-Mail g.y.h.lip@bham.ac.uk

  Article Information

Number of Print Pages : 6
Number of Figures : 4, Number of Tables : 1, Number of References : 26

  Publication Details

Pathophysiology of Haemostasis and Thrombosis

Vol. 34, No. Suppl. 1, Year 2005 (Cover Date: February 2005)

Journal Editor: Rosing, J. (Maastricht)
ISSN: 1424-8832 (print), 1424-8840 (Online)

For additional information: http://www.karger.com/pht

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.